The PTEN/PI3K/AKT pathway is altered in 42% of primary and 100% of metastatic cases; loss of PTEN and activation of the PI3K/AKT signaling pathway are hallmarks of prostate cancer, and cooperate with the activation of the RAS/MAPK pathway to promote EMT and metastatic CRPC development. The gene discussed is AKT1; the disease is prostate carcinoma.